Results 51 to 60 of about 14,308 (181)

Polineuropatia desmielinizante inflamatória crônica pós-tratamento com interferon peguilado alfa 2b em um paciente co-infectado HIV/HCV: relato de caso Chronic inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alpha 2b in a patient with HIV/HCV coinfection: case report

Revista da Sociedade Brasileira de Medicina Tropical, 2010
A polineuropatia desmielinizante inflamatória cônica possui forte associação com a infecção pelo HIV e HCV. Uma rara associação entre PDIC e o tratamento da hepatite C com interferon peguilado alfa foi descrita recentemente.
Bil Randerson Bassetti, Eduardo Sturzeneker Trés, Jovana Gobbi Marchesi Ciríaco, Lauro Ferreira Silva Pinto Neto   +3 more
doaj   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Biofluid Biomarkers of Cognitive Functioning in Bipolar Disorder: A Systematic Review by the Targeting Cognition and Older‐Age Bipolar Disorder ISBD Task Forces

Bipolar Disorders, Volume 28, Issue 5, August 2026.
ABSTRACT Background Cognitive impairment is common in bipolar disorder (BD), but the underlying pathophysiology remains unclear. This systematic review aimed to (1) summarize all literature describing relationships of biofluid biomarkers and cognition in BD and (2) identify which biofluid biomarkers correlate most consistently with cognition in BD ...
Alexandra J. M. Beunders, Sigfried N. T. M. Schouws, Andrew T. Olagunju, Vicent Balanzá‐Martínez, Nicole C. M. Korten, Ralph W. Kupka, Katherine E. Burdick, Andre F. Carvalho, Ariel G. Gildengers, Lars V. Kessing, Roger S. McIntyre, Paula V. Nunes, Ayal Schaffer, Ivan J. Torres, Shang‐Ying Tsai, Tamsyn E. Van Rheenen, Eduard Vieta, Lakshmi N. Yatham, Allan H. Young, Lisa T. Eyler, Kamilla W. Miskowiak, Annemiek Dols   +21 more
wiley   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy

Brazilian Journal of Infectious Diseases
Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients.
E. Parise, H. Cheinquer, D. Crespo, A. Meirelles, A. Martinelli, H. Sette, J. Gallizi, R. Silva, C. Lacet, E. Correa, H. Cotrim, J. Fonseca, R. Paraná, V. Spinelli, W. Amorim, F. Tatsch, M. Pessoa   +16 more
doaj   +1 more source

An Exploratory Cost‐Utility Analysis of Screening and Treating Immigrants in Canada for Hepatitis D

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT Hepatitis D is common among immigrants in Canada, who account for approximately 23% of the population and tend to originate from high‐endemic countries. Mortality rates are notably high among those with chronic infections, and immigrants are less likely to engage in screening and treatment services.
Jiahao Zhao, Diedron Lewis, John‐Michael Gamble, Zahid A. Butt, William W. L. Wong   +4 more
wiley   +1 more source

The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon

Journal of Translational Medicine, 2012
Background Blood biomarkers are needed to monitor anti-angiogenic treatments for cancer. The association of blood levels of microRNAs (miRs) implicated in angiogenesis with circulating endothelial cells (CEC) and with angiogenic proteins was examined in ...
Triozzi Pierre L, Achberger Susan, Aldrich Wayne, Singh Arun D, Grane Ronald, Borden Ernest C   +5 more
doaj   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Multisystem sarcoidosis in a patient on interferon-α therapy for chronic hepatitis C

Journal of Global Infectious Diseases, 2012
Sarcoidosis is a chronic multisystemic granulomatous disease that is triggered by an autoimmune process. Nowadays, this pathology represents a well-recognized but uncommon complication for antiviral treatment in hepatitis C virus (HCV) infection. Herein,
Bouchra Oudghiri, Mohammed Benzagmout, Saïd Boujraf, Faouzi Belahcen, Adil Ibrahimi   +4 more
doaj   +1 more source

El tratamiento de 24 semanas con PEG interferón alfa 2a podría ser similar al de 48 semanas en pacientes con hepatitis B crónica HBeAg positivo y buenos predictores de respuesta: resultados de un estudio piloto

Acta Gastroenterológica Latinoamericana, 2009
Introducción. El tratamiento recomendado para los pacientes con hepatitis B crónica HBeAg positivo es PEG interferón alfa 2a durante 48 semanas. No hay suficientes datos que avalen mejor respuesta con 48 semanas de tratamiento versus 24 semanas.
Joaquín Solari, Omar Galdame, Lucrecia Rezzonico, Bernardo Frider, Alejandra Villamil, Paola Casciato, María Reig, Juan Carlos Bandi, Analía Alessio, Adrián Gadano   +9 more
doaj